PL3618875T3 - Terapia skojarzona obejmująca inhibitor raf i trametynib - Google Patents
Terapia skojarzona obejmująca inhibitor raf i trametynibInfo
- Publication number
- PL3618875T3 PL3618875T3 PL18726224.1T PL18726224T PL3618875T3 PL 3618875 T3 PL3618875 T3 PL 3618875T3 PL 18726224 T PL18726224 T PL 18726224T PL 3618875 T3 PL3618875 T3 PL 3618875T3
- Authority
- PL
- Poland
- Prior art keywords
- trametinib
- combination therapy
- raf inhibitor
- raf
- inhibitor
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 title 1
- 229960004066 trametinib Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Iron Core Of Rotating Electric Machines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762500108P | 2017-05-02 | 2017-05-02 | |
| US201862656423P | 2018-04-12 | 2018-04-12 | |
| PCT/IB2018/052989 WO2018203219A1 (en) | 2017-05-02 | 2018-04-30 | Combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3618875T3 true PL3618875T3 (pl) | 2023-10-23 |
Family
ID=62218018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18726224.1T PL3618875T3 (pl) | 2017-05-02 | 2018-04-30 | Terapia skojarzona obejmująca inhibitor raf i trametynib |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11266653B2 (pl) |
| EP (2) | EP3618875B1 (pl) |
| JP (2) | JP7309614B2 (pl) |
| KR (2) | KR20240032157A (pl) |
| CN (1) | CN110494166B (pl) |
| AU (1) | AU2018262891B2 (pl) |
| BR (1) | BR112019022511A2 (pl) |
| CA (1) | CA3057969A1 (pl) |
| CL (1) | CL2019003091A1 (pl) |
| DK (1) | DK3618875T3 (pl) |
| ES (1) | ES2952265T3 (pl) |
| FI (1) | FI3618875T3 (pl) |
| IL (2) | IL270224B1 (pl) |
| MX (1) | MX2019012884A (pl) |
| PL (1) | PL3618875T3 (pl) |
| PT (1) | PT3618875T (pl) |
| TW (1) | TWI798218B (pl) |
| WO (1) | WO2018203219A1 (pl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019033123A1 (en) * | 2017-08-11 | 2019-02-14 | Curematch, Inc. | DRUG ASSOCIATIONS FOR TARGETING MULTIPLE MUTATIONS IN CANCER |
| KR20210105388A (ko) * | 2018-12-20 | 2021-08-26 | 노파르티스 아게 | 암 치료에서 사용하기 위한 raf 저해제와 cdk4/6 저해제를 이용하는 병용요법 |
| US20230226030A1 (en) * | 2020-02-18 | 2023-07-20 | Novartis Ag | Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc |
| JPWO2021172582A1 (pl) * | 2020-02-27 | 2021-09-02 | ||
| CN113440616A (zh) * | 2020-03-25 | 2021-09-28 | 上海科州药物研发有限公司 | Ras或raf突变型癌症的联合疗法 |
| JP2023525100A (ja) * | 2020-05-12 | 2023-06-14 | ノバルティス アーゲー | Ｃｒａｆ阻害剤を含む治療的組み合わせ |
| EP4203963A1 (en) * | 2020-08-31 | 2023-07-05 | Novartis AG | Combination therapy of a raf inhibitor and a mek inhibitor for the treatment of sarcoma |
| WO2023145530A1 (ja) * | 2022-01-27 | 2023-08-03 | 国立大学法人東北大学 | 癌治療剤 |
| WO2023166345A2 (en) | 2022-03-02 | 2023-09-07 | Novartis Ag | Precision therapy for the treatment of cancer |
| WO2024054591A1 (en) | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| WO2024088273A1 (zh) * | 2022-10-25 | 2024-05-02 | 中国科学院上海药物研究所 | 一种萘酰胺化合物治疗kras突变相关疾病的用途 |
| WO2024088275A1 (zh) * | 2022-10-25 | 2024-05-02 | 中国科学院上海药物研究所 | 一种萘酰胺化合物治疗耐药性肿瘤的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU2503A (sh) | 2000-07-19 | 2006-05-25 | Warner-Lambert Company | Oksigenovani estri 4-jodo fenilamino benzhidroksamskih kiselina |
| MXPA06014478A (es) | 2004-06-11 | 2007-03-21 | Japan Tobacco Inc | Derivados de 5-amino-2, 4, 7-trioxo-3, 4, 7, 8-tetrahidro -2h-pirido[2, 3-d]pirimidina y compuestos relacionados para el tratamiento del cancer. |
| TWI505828B (zh) | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產（第二）有限公司 | 新穎醫藥組成物 |
| AR091876A1 (es) * | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
| KR102134585B1 (ko) * | 2012-09-04 | 2020-07-17 | 노바르티스 아게 | 보조 암 치료 방법 |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| EP3515446B1 (en) | 2016-09-19 | 2023-12-20 | Novartis AG | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
-
2018
- 2018-04-30 CA CA3057969A patent/CA3057969A1/en active Pending
- 2018-04-30 PT PT187262241T patent/PT3618875T/pt unknown
- 2018-04-30 KR KR1020247006274A patent/KR20240032157A/ko active Search and Examination
- 2018-04-30 US US16/610,482 patent/US11266653B2/en active Active
- 2018-04-30 TW TW107114676A patent/TWI798218B/zh active
- 2018-04-30 WO PCT/IB2018/052989 patent/WO2018203219A1/en unknown
- 2018-04-30 CN CN201880023601.0A patent/CN110494166B/zh active Active
- 2018-04-30 DK DK18726224.1T patent/DK3618875T3/da active
- 2018-04-30 AU AU2018262891A patent/AU2018262891B2/en active Active
- 2018-04-30 FI FIEP18726224.1T patent/FI3618875T3/fi active
- 2018-04-30 IL IL270224A patent/IL270224B1/en unknown
- 2018-04-30 KR KR1020197031788A patent/KR102641827B1/ko active IP Right Grant
- 2018-04-30 EP EP18726224.1A patent/EP3618875B1/en active Active
- 2018-04-30 PL PL18726224.1T patent/PL3618875T3/pl unknown
- 2018-04-30 BR BR112019022511-0A patent/BR112019022511A2/pt unknown
- 2018-04-30 JP JP2019558725A patent/JP7309614B2/ja active Active
- 2018-04-30 EP EP23166366.7A patent/EP4272740A1/en active Pending
- 2018-04-30 ES ES18726224T patent/ES2952265T3/es active Active
- 2018-04-30 IL IL311471A patent/IL311471A/en unknown
- 2018-04-30 MX MX2019012884A patent/MX2019012884A/es unknown
-
2019
- 2019-10-28 CL CL2019003091A patent/CL2019003091A1/es unknown
-
2022
- 2022-01-26 US US17/584,901 patent/US20220143036A1/en active Pending
-
2023
- 2023-07-05 JP JP2023110949A patent/JP2023145467A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4272740A1 (en) | 2023-11-08 |
| AU2018262891A1 (en) | 2019-10-17 |
| ES2952265T3 (es) | 2023-10-30 |
| TWI798218B (zh) | 2023-04-11 |
| KR20240032157A (ko) | 2024-03-08 |
| PT3618875T (pt) | 2023-08-07 |
| KR20190141164A (ko) | 2019-12-23 |
| AU2018262891B2 (en) | 2021-04-01 |
| IL311471A (en) | 2024-05-01 |
| KR102641827B1 (ko) | 2024-03-04 |
| RU2019134757A (ru) | 2021-06-02 |
| DK3618875T3 (da) | 2023-07-10 |
| US20220143036A1 (en) | 2022-05-12 |
| EP3618875B1 (en) | 2023-04-05 |
| US20200246346A1 (en) | 2020-08-06 |
| US11266653B2 (en) | 2022-03-08 |
| FI3618875T3 (fi) | 2023-07-04 |
| IL270224A (pl) | 2019-12-31 |
| CA3057969A1 (en) | 2018-11-08 |
| BR112019022511A2 (pt) | 2020-05-12 |
| JP7309614B2 (ja) | 2023-07-18 |
| WO2018203219A1 (en) | 2018-11-08 |
| RU2019134757A3 (pl) | 2021-08-17 |
| CN110494166B (zh) | 2022-11-08 |
| TW201842914A (zh) | 2018-12-16 |
| EP3618875A1 (en) | 2020-03-11 |
| IL270224B1 (en) | 2024-04-01 |
| JP2020518568A (ja) | 2020-06-25 |
| MX2019012884A (es) | 2020-01-14 |
| JP2023145467A (ja) | 2023-10-11 |
| CL2019003091A1 (es) | 2020-02-07 |
| CN110494166A (zh) | 2019-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3618875T3 (pl) | Terapia skojarzona obejmująca inhibitor raf i trametynib | |
| IL264931B (en) | Medicinal combinations containing a raf inhibitor and an erk inhibitor | |
| EP3397359A4 (en) | THERAPY AND BODY TRAINING DEVICE | |
| IL293377B1 (en) | Variants of hsd17b13 and their uses | |
| IL262378A (en) | Compositions and methods containing a capsid assembly inhibitor | |
| GB201707153D0 (en) | Therapy | |
| ZA201606349B (en) | Radiotherapy board and couch | |
| EP3572400C0 (en) | EZH2 INHIBITOR AND ITS USE | |
| PT3582838T (pt) | Inaladores e métodos relacionados | |
| PT3582839T (pt) | Inalador | |
| LT3621694T (lt) | Lrrc33 inhibitoriai ir jų panaudojimas | |
| HUE063848T2 (hu) | LSD1 gátlók és gyógyászati alkalmazásaik | |
| IL255530A (en) | Efflux-pump inhibitors and therapeutic uses thereof | |
| GB201708663D0 (en) | Therapy | |
| GB201719646D0 (en) | Therapy | |
| PT3582837T (pt) | Inaladores | |
| GB201715194D0 (en) | Compounds and their therapeutic use | |
| IL261505A (en) | Combined treatment using liv1-adc and a chemotherapeutic agent | |
| HK1247619A1 (zh) | 使用抗 dc 19抗體–藥物共軛物及長春新鹼的聯合治療 | |
| IL270011B (en) | Medicinal compounds and methods | |
| GB201700526D0 (en) | Therapeutic use | |
| GB201820761D0 (en) | Defibrillator status indication and activation | |
| GB201711401D0 (en) | A new exciting and adaptable table game | |
| GB201715430D0 (en) | Therapy | |
| PL3354163T3 (pl) | Materac przenośny |